Mironid’s ShoLo® and LoAc® programmes benefit from a close association with Dr George Muller as a key medicinal chemistry and experienced drug development advisor.  George

C3 inhibitor is in development for the treatment of PNH, both in patients not previously treated with eculizumab, and in patients who continue to experience

Glasgow, Scotland, and Sheffield, UK, 12th December 2016 –  Mironid Ltd, a leader in cell signalling-directed drug development, and the University of Sheffield, announced today

Mironid is delighted to announce that Prof Albert Ong DM MA FRCP, Professor of Renal Medicine, Department of Infection Immunity & Cardiovascular Disease, University of

Louisville, Ky., December 2, 2016 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present positive interim

Brighton, UK, November 10, 2016: Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of

Originally published October 31, 2016 in Invest Edinburgh A new biotech company called Nodthera has been launched in Edinburgh to develop potential treatments for a